Sodium Bicarbonate [Ear Preparations] interactions
Checked as Sodium bicarbonate in this data source.
Full monograph for Sodium Bicarbonate [Ear Preparations]Check it against another medicine
Medicines
459 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Selpercatinib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in… | 2 sources — open the full entry |
| Sotorasib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma. | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Absorption | INTERVAL: Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of acalabrutinib and reduce its… | 2 sources — open the full entry |
| Aspirin | Moderate | Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other… | 5 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Excretion · Unknown | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other…2 documented mechanisms | 5 sources — open the full entry |
| Atropine Sulfate (Injection) | Moderate | Absorption | INTERVAL: Concurrent administration of antacids or adsorbent antidiarrheal agents may decrease the oral bioavailability of atropine. | 1 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other… | 5 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Absorption · Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other…2 documented mechanisms | 8 sources — open the full entry |
| Bisacodyl | Moderate | Absorption | INTERVAL: By increasing gastric pH, antacids may reduce the resistance of the enteric coating of bisacodyl tablets, resulting in earlier release of bisacodyl… | 1 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Cefditoren | Moderate | Absorption | Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil. | 2 sources — open the full entry |
| Cefpodoxime Proxetil | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefuroxime Axetil | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Ceritinib | Moderate | Absorption | Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been… | 2 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Moderate | Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other… | 5 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Moderate | Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria. | 2 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Absorption · Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.2 documented mechanisms | 5 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Moderate | Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria. | 2 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine | Moderate | Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria. | 2 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Moderate | Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other… | 5 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Excretion · Unknown | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other…2 documented mechanisms | 5 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Moderate | Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other… | 5 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Moderate | Absorption | Coadministration with an antacid may reduce the bioavailability of dabigatran following oral administration of dabigatran etexilate. | 1 sources — open the full entry |
| Dasatinib | Moderate | Absorption | INTERVAL: Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, coadministration with antacids or agents with… | 4 sources — open the full entry |
| Dexamethasone + Levofloxacin | Moderate | Absorption · Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.2 documented mechanisms | 5 sources — open the full entry |
| Dextromethorphan + Pseudoephedrine + Triprolidine | Moderate | Excretion | Alkalization of the urine decreases the urinary excretion increases the elimination half-life of ephedrine, pseudoephedrine, and related drugs. Toxicity from… | 3 sources — open the full entry |
| Dithranol + Boric Acid + Salicylic Acid | Moderate | Excretion | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other… | 5 sources — open the full entry |
| Doxycycline Hydrochloride | Moderate | Excretion | INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve… | 5 sources — open the full entry |
| Ephedrine Hydrochloride | Moderate | Excretion | Alkalization of the urine decreases the urinary excretion increases the elimination half-life of ephedrine, pseudoephedrine, and related drugs. Toxicity from… | 3 sources — open the full entry |
| Erlotinib | Moderate | Absorption | INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of erlotinib and reduce… | 6 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Ferric Maltol | Moderate | Absorption | The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The… | 12 sources — open the full entry |
| Ferrous Fumarate + Folic acid | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Gatifloxacin | Moderate | Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria. | 2 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Moderate | Absorption · Excretion | Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.2 documented mechanisms | 5 sources — open the full entry |
| Glibenclamide | Moderate | Absorption | INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic… | 17 sources — open the full entry |
| Glipizide | Moderate | Absorption | INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic… | 17 sources — open the full entry |
| Glipizide + Metformin Hydrochloride | Moderate | Absorption · Unknown | INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic…2 documented mechanisms | 17 sources — open the full entry |
| Iron + Folic Acid + Vitamin A + Vitamin C + Zinc | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Iron + Folic acid + Vitamin B complex + Vitamin C | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate | Moderate | Absorption · Unknown | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Iron Polymaltose Complex | Moderate | Absorption | The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The… | 12 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc + Vitamin B-Complex | Moderate | Absorption · Unknown | The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The…2 documented mechanisms | 12 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfate | Moderate | Absorption · Unknown | The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The…2 documented mechanisms | 12 sources — open the full entry |
| Iron Polymaltose Complex + Vitamin B Complex + Zinc | Moderate | Absorption | The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The… | 12 sources — open the full entry |
| Itraconazole | Moderate | Absorption | INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the… | 15 sources — open the full entry |
Conditions
Conditions in which Sodium Bicarbonate [Ear Preparations] needs care, as documented in this source.
Water-Electrolyte Imbalance
MajorAlkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.
2 sources
- "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals (2001):
- "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical (2001):
Acid-Base Imbalance
ModerateAlkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions. Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis. Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release. Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function. Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.
3 sources
- "Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company
- "Product Information. Tham (tromethamine)." Abbott Pharmaceutical (2001):
- "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical (2001):